Film-coated tablet production for diabetic polyneuropathy begins with alpha-lipoic acid of Ph. Eur. monograph quality and a documented particle-size distribution that is shifted away from the fine fraction because the bulk drug substance exhibits a melting point of 60–62 °C, plate-like crystal habit and low compressibility. Direct compression is not used at production scale; instead the API is dry-granulated on a roller compactor with cooled rolls operated so that roll surface temperature does not exceed 35 °C and the mill screen aperture is set between 0.8 mm and 1.25 mm. Granule fines below 150 µm are held below 30% of total granule mass to prevent die filling variation, punch adhesion and visible picking on rotary tablet presses. A standard tablet core at 600 mg alpha-lipoic acid has a target core mass of 850 mg, corresponding to an API loading of 70.6% w/w; the remaining mass consists of microcrystalline cellulose 12–18% w/w, crospovidone 2–4% w/w, colloidal silicon dioxide 0.5–1.5% w/w, and magnesium stearate 0.5–1.0% w/w. Compression is performed on an 18-station rotary press equipped with oblong punches at a compression force of 12–20 kN, and the press is run with cooled punch tips to avoid the low-melting-point fraction softening at the punch face. The compressed cores are film-coated with an aqueous hypromellose-based coating containing titanium dioxide and iron oxide, applied to a weight gain of 2.5–3.5% w/w, which provides a light barrier and reduces the sulfur odor during storage.

Compendial release testing for the film-coated tablet includes assay by liquid chromatography according to Ph. Eur. 2.2.29, content uniformity according to USP <905>, dissolution in 0.1 N hydrochloric acid according to USP <711> with a sampling program appropriate for an immediate-release oral solid, and elemental impurity control according to ICH Q3D. Residual solvent limits follow ICH Q3C where ethanol or isopropanol is used during granulation. Batch records document drying oven or fluid-bed drying end points by loss on drying according to Ph. Eur. 2.2.32, and the final finished dosage form is a light-protective film-coated tablet marketed in PVC/PVDC/aluminum or PA/aluminum/PVC blisters. Published data for specific punch geometry is limited; manufacturers therefore qualify die-bed temperature, granule particle size and punch polish as in-house technical release parameters before scale-up.

When Capsule Fill Mass Requires Nitrogen Blanketing and Desiccated Hopper Conditions

Hard capsule filling of alpha-lipoic acid is constrained less by the capsule shell chemistry than by the API’s hygroscopicity, low melting point and propensity to electrostatically adhere to metal and polymer contact surfaces. A 300 mg dose is typically filled into a size 1 hydroxypropylmethylcellulose or hard gelatin capsule with a total fill mass of 420 mg, giving an API fraction of 71.4% w/w. Direct blending uses a low-shear tumble blender charged to 60% of working volume, and the blend is protected with a nitrogen overlay at 0.2–0.5 bar positive pressure to limit oxidative discolouration. The powder mixture includes mannitol or pregelatinized starch 15–22% w/w, croscarmellose sodium 2–4% w/w, colloidal silicon dioxide 0.5–1.5% w/w, and magnesium stearate 0.5–1.0% w/w. Relative humidity in the encapsulation suite is maintained below 40% RH, and the capsule hopper is fitted with a desiccated air purge to prevent powder bridging and inconsistent dosator fill weight.

Compliance for the hard capsule follows USP <711> or Ph. Eur. 2.9.3 dissolution testing, USP <905> content uniformity, and ICH Q3D elemental impurity limits. The terminal finished product is a hard oral capsule in 300 mg or 600 mg strengths, packaged in high-barrier blister film. Production-scale equipment failure modes include dosator pin clogging when the API particle size has a d90 above 500 µm and split capsule shells when the fill mass contains residual granule moisture above 1.0% by Karl Fischer titration. A pre-processing moisture specification of NMT 0.5% w/w for the blended powder is applied.

Granule Porosity and Dissolution Lag in Fluidized-Bed Sachet Manufacture

Granule-filled sachets for oral solution or direct oral administration are formulated as single-dose units containing 600 mg alpha-lipoic acid in a total sachet mass of 1.8–2.2 g, corresponding to an API loading of 27–33% w/w. The granulation process uses a fluid-bed top-spray configuration with an ethanolic or isopropanolic binder solution of povidone K30 at 2–4% w/w of dry granule mass. Inlet air temperature is limited to 35–45 °C and product temperature is kept at 28–32 °C because alpha-lipoic acid softens near 60 °C and can fuse into agglomerates inside the filter bag assembly. Mannitol, xylitol or sorbitol is used as a water-soluble bulking agent at 55–65% w/w, and a citric acid/sodium bicarbonate effervescent pair, when present, is added as a separately dried pre-mix at 10–15% w/w to prevent premature reaction during granulation. The finished granules are sieved to 0.5–1.4 mm, and sachet filling is conducted below 30% RH in stick-pack or four-side-seal aluminum foil laminate. The laminate is specified with a water vapour transmission rate below 0.1 g/m²/day at 38 °C and 90% RH when tested according to ASTM F1249.

Compliance for granule sachets is assessed by Ph. Eur. 2.9.1 for disintegration/dissolution of granules, USP <905> for delivered-dose uniformity of single-dose containers, and ICH Q3D for elemental impurities. Residual moisture after drying is controlled to NMT 0.8% w/w by Karl Fischer titration according to Ph. Eur. 2.5.12. Terminal finished product types are sachets and stick packs for oral solution, intended for patients with dysphagia or for administration through enteral tubes after dispersion in water; the dosage form is not suitable for reconstitution in acidic beverages because the effervescent system may alter dissolution and reduce API stability.

What Limits the pH Window for Aqueous Thioctic Acid Infusion Concentrates?

Aqueous injectable dosage forms of alpha-lipoic acid are prepared as sterile concentrates because the free acid has poor water solubility and undergoes oxidative degradation in unbuffered solution. A 600 mg dose is formulated at 30 mg/mL in 20 mL of water for injection, using meglumine or trometamol as a molar-equivalent solubilizing and pH-adjusting agent; the resulting solution is adjusted to pH 8.2–8.8 because lower pH values lead to precipitation of the free acid and higher pH values accelerate ring-opening or thiol-disulfide exchange reactions. The compounding vessel is a jacketed stainless steel mixer purged with filtered nitrogen before and during dissolution, with dissolved oxygen measured below 0.2 mg/L in the bulk solution. The solution is sterile-filtered through a 0.22 µm polyvinylidene fluoride membrane and filled into amber Type I borosilicate glass vials or ampoules under Grade A laminar flow within a Grade B background, in accordance with EU GMP Annex 1. The filling line is operated with a nitrogen headspace purge and light-shielded from dissolving tank to crimping station to limit photolytic discolouration.

Compendial compliance for the injection includes visible particulate testing according to USP <790>, sub-visible particulate matter according to USP <788>, bacterial endotoxins according to USP <85>, and elemental impurities according to ICH Q3D. Container glass is specified against Ph. Eur. 3.2.1 and closure compatibility is verified over long-term and accelerated conditions. The terminal finished product is a sterile concentrate for solution for infusion that is diluted into 0.9% w/v sodium chloride solution before intravenous administration; the diluted infusion must be protected from light and used within the validated in-use stability period. Published data for alternative container materials is limited, and PVC infusion bags should not be used without light-protective overwrap because alpha-lipoic acid adsorbs to certain plastic surfaces and photodegradation occurs rapidly in unprotected administration sets.

Lyophilized powder for solution for infusion is selected when a ready-to-use liquid would incur excessive thermal and photolytic degradation during storage. The pre-lyophilization solution contains alpha-lipoic acid at 30 mg/mL, mannitol as a crystallizing bulking agent at 10 mg/mL, and meglumine in a molar-equivalent amount to form a soluble salt, giving a total solids content of approximately 4.0–4.5% w/w. The fill volume is 20 mL, delivering 600 mg alpha-lipoic acid per vial after lyophilization. Freezing is performed on a shelf ramp to -40 °C over 2–3 h, followed by primary drying at a shelf temperature of -20 °C and chamber pressure of 0.1–0.2 mbar; secondary drying is conducted at 25 °C until the cake moisture is ≤2.0% w/w by Karl Fischer titration. Collapse of the lyophilized cake is observed when total solids fall below 2.5% w/w, and processing experience shows that uncontrolled nucleation results in a glassy, collapsed ring at the vial wall and elevated reconstitution time above 3 min.

Compliance for the lyophilized powder includes water determination according to USP <921>, sub-visible particulate matter after reconstitution according to USP <788>, bacterial endotoxins according to USP <85>, and sterility testing according to Ph. Eur. 2.6.1. The container-closure system is an amber or clear Type I glass vial with a bromobutyl rubber stopper and flip-off seal; the terminal product is a sterile powder for concentrate for solution for infusion, reconstituted with water for injection to 30 mg/mL before dilution into 0.9% w/v sodium chloride. This dosage form is operationally bounded by the need for light-protected reconstitution and by the limited physical stability of the reconstituted solution, which must be used within the validated in-use holding time.